This biomarker analysis of the SOLAR-1 trial showed that alpelisib plus fulvestrant had a clinical benefit regardless of the gene mutation status in patients with HR+, HER2− advanced breast cancer (ABC), including those with FGFR1 or FGFR2 alterations. A limited benefit of alpelisib was noted in patients with the MYC mutation compared with placebo.
The clinical benefit with alpelisib plus fulvestrant was maintained in this patient population, regardless of alterations in most biomarkers, including ESR1 and genes implicated in CDK4/6i resistance (eg, CCND1, MAP3K1, and FGFR).
– Jing Xi, MD, MPH
Written by
Hazelgreen
To view profiles and participate in discussions please or .
Thanks so much for sharing - the 'take home' is hugely appreciated. I'm waiting to see if I develop the mutation to get me on a trial for the oral SERD but as it's double blind, I think I will push for swapping in fulvestrant in place of letrozole instead.All the best,
"Alpelisib is a novel therapy approved for HR-positive, HER2-negative breast cancer in patients who have progressed on first-line hormonal therapies. Alpelisib's novel mechanism selectively inhibits the PI3K pathway, a driver mutation found in HR-positive, HER2-negative breast cancers."
"What kind of drug is alpelisib? Alpelisib is in a class of medications called kinase inhibitors. It works by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells."
I don’t do a deep dive into the links, but I like the summary, and it provides hope that research is coming up with effective treatments for the future.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Good News re: CDK4/6 Inhibitors & Overall Survival 
Latest Details on Approval of Oral SERDS - In Place of Faslodex Shots
